Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Abstract Belantamab mafodotin (belamaf) is an antibody–drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (c...

Full description

Bibliographic Details
Main Authors: Chetan Rathi, Jon Collins, Herbert Struemper, Joanna Opalinska, Roxanne C. Jewell, Geraldine Ferron‐Brady
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12660

Internet

https://doi.org/10.1002/psp4.12660

Similar Items